focus -WSS

focus

author：Wikipedia 2025-10-02 00:18:01 - browse：9

Illustration of a dollar sign with arrows. — Adobe

Health insurers are telling shareholders that they are ramping up the use of artificial intelligence and are hiring talent to implement the technology across their organizations. They say their artificial intelligence models can increase efficiency and “cut costs,” but they refused to discuss what models they’re using, how those models were developed, or exactly what they’re using them for.

Centene, for instance, says, it is “investing in artificial intelligence and machine learning technologies to improve the health of our members and contain rising healthcare costs.” The insurer, whose plans cover more than 28 million Americans, noted that its large footprint, particularly in government-sponsored programs, puts it “in a unique position to use data to develop models that predict a wide range of health outcomes.”

A STAT review of regulatory filings from publicly traded health insurers showed that several of them, including Elevance, Molina, and Cigna, are investing in AI with the goal of saving money. Elevance has hired nearly 500 people to work exclusively on AI. However, all five of the insurers STAT contacted declined to elaborate on how they are using AI.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Medicare bonuses could stop drug shortages under Senate plan

Wikipedia

WSS

Why sickle cell disease is getting the first CRISPR treatment

Spinal cord stimulation reduces pain in amputees, study finds

CMS should re

Mass General, Mayo Clinic look to monetize custom

SCOTUS to consider access to abortion pill mifepristone

Pharma patents targeted by Biden in move to slash drug prices

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

Immunocompromised patients offer clues on chronic Covid

Hepatitis C has a cure — but many Americans still lack access to it

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Peter Hotez and the public health issue of online harassment

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Jerome Adams on the need for new antivirals for Covid

There's an unseen cost to disruptive road

Affirmative action in medical school literally saved lives

Prior authorization reform is both possible and imperative

explore

Dog Aging Project founders on what lies ahead after losing funding

Patients' immediate access to test results puts radiologists in a bind

Head of FDA's diagnostics center, who led through Covid, retires

Mass General, Mayo Clinic look to monetize custom

Pharma patents targeted by Biden in move to slash drug prices

Printout prescription drug information shouldn’t go digital

Wikipedia

explore

hotspot

focus